Integra LifeSciences Holdings
$ 17.90
5.67%
09 Jun - close price
- Market Cap 1,317,880,000 USD
- Current Price $ 17.90
- High / Low $ 18.05 / 17.08
- Stock P/E N/A
- Book Value 13.39
- EPS -6.47
- Next Earning Report 2026-07-30
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.03 %
- ROE -0.39 %
- 52 Week High 18.05
- 52 Week Low 8.70
About
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, limb reconstruction, orthopedics, and general surgery. The company is headquartered in Princeton, New Jersey.
Analyst Target Price
$17.43
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-05 | 2026-02-26 | 2025-10-30 | 2025-07-31 | 2025-05-05 | 2025-02-25 | 2024-11-04 | 2024-07-29 | 2024-05-06 | 2024-02-28 | 2023-10-25 | 2023-07-26 |
| Reported EPS | 0.54 | 0.83 | 0.54 | 0.45 | 0.41 | 0.97 | 0.41 | 0.63 | 0.55 | 0.89 | 0.76 | 0.71 |
| Estimated EPS | 0.4 | 0.8002 | 0.43 | 0.43 | 0.43 | 0.8554 | 0.39 | 0.62 | 0.55 | 0.9 | 0.78 | 0.57 |
| Surprise | 0.14 | 0.0298 | 0.11 | 0.02 | -0.02 | 0.1146 | 0.02 | 0.01 | 0 | -0.01 | -0.02 | 0.14 |
| Surprise Percentage | 35% | 3.7241% | 25.5814% | 4.6512% | -4.6512% | 13.3972% | 5.1282% | 1.6129% | 0% | -1.1111% | -2.5641% | 24.5614% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-07-30 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | 0.49 |
| Currency | USD |
Previous Dividend Records
| Jan 1970 | |
|---|---|
| Payment Date | None |
| Amount | $6.37 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: IART
2026-06-09 15:11:02
Integra LifeSciences Holdings (IART) stock has reached a 52-week high at $17.84, driven by impressive year-to-date gains of 36.39% and strong first-quarter 2026 financial results that surpassed analyst expectations. The company reported adjusted earnings per share of $0.54 and revenue of $392 million, reflecting robust growth and market confidence. Despite the high, InvestingPro analysis suggests the stock may still be undervalued, indicating potential for further upside.
2026-06-03 21:09:08
Michael J. McBreen, EVP & Chief Commercial Officer at Integra LifeSciences Holdings Corp (IART), was granted 31,909 restricted stock units and a non-qualified stock option for 60,372 shares with an exercise price of $15.67. Both awards vest in three equal annual installments, contingent on his continued service. Following the RSU grant, McBreen directly holds 124,017 shares of common stock.
2026-06-03 21:09:08
Integra LifeSciences Holdings Corp (IART) CEO Stuart Essig was granted 365,297 Restricted Stock Units (RSUs) and 705,468 non-qualified stock options on June 1, 2026. These awards, part of his employment agreement and at the discretion of the Compensation Committee, will vest over 25 months starting May 1, 2026. The stock options have an exercise price of $15.6700 per share.
2026-06-02 13:40:16
Hagens Berman is reminding investors of Integra LifeSciences Holdings Corp. (NASDAQ: IART) about a pending securities fraud class action lawsuit. The lawsuit alleges that Integra made misleading statements and failed to disclose Good Manufacturing Practices violations at its Boston Facility, leading to a global recall of products and a significant drop in stock prices. The firm encourages investors who suffered substantial losses to contact their attorneys for legal consultation.
2026-06-02 11:09:41
Integra LifeSciences announced that its Chief Financial Officer, Lea Knight, will present at the 2026 Jefferies Global Healthcare Conference on June 3, 2026, at 10:30 AM ET. A live webcast of the presentation will be available on the company's investor relations website. This presentation is part of Integra LifeSciences' ongoing investor relations efforts, which have recently included positive reactions from leadership changes and strong Q1 2026 financial results.
2026-06-02 07:30:00
Integra LifeSciences Holdings Corporation announced that CFO Lea Knight will present at the 2026 Jefferies Global Healthcare Conference on June 3, 2026, at 10:30 a.m. ET. A live webcast of the presentation will be available on the company's investor relations website. The company is a global medical technology leader focused on neurosurgery and tissue reconstruction.
